Terms: = Ovarian cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
17 results:
1. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
2. ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacological inhibition of ezh2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract] [Full Text] [Related]
4. The epigenetic factor CHD4 contributes to metastasis by regulating the ezh2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
5. Dual G9A/ezh2 Inhibition Stimulates Antitumor Immune Response in ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
6. ezh2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
7. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to ezh2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract] [Full Text] [Related]
8. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated ezh2 and SIRT1.
Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
[TBL] [Abstract] [Full Text] [Related]
9. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of enhance of Zeste homolog 2 (ezh2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
[TBL] [Abstract] [Full Text] [Related]
11. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract] [Full Text] [Related]
12. An integrated analysis reveals the oncogenic function of lncRNA LINC00511 in human ovarian cancer.
Wang J; Tian Y; Zheng H; Ding Y; Wang X
Cancer Med; 2019 Jun; 8(6):3026-3035. PubMed ID: 31016892
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA LSINCT5 acts as an oncogene via increasing ezh2-induced inhibition of APC expression in osteosarcoma.
Kong D; Li C; Yang Q; Wei B; Wang L; Peng C
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):193-197. PubMed ID: 30420287
[TBL] [Abstract] [Full Text] [Related]
14. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract] [Full Text] [Related]
15. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract] [Full Text] [Related]
16. The role of ezh2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer.
Wang J; Yu L; Cai J; Jia J; Gao Y; Liang M; Wang Z
Biochem Biophys Res Commun; 2013 Apr; 433(4):470-6. PubMed ID: 23523787
[TBL] [Abstract] [Full Text] [Related]
17. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]